Increasing JAK/STAT Signaling Function of Infant CD4+ T Cells during the First Year of Life by Myra Grace dela Peña-Ponce et al.
February 2017 | Volume 5 | Article 151
Original research
published: 21 February 2017
doi: 10.3389/fped.2017.00015
Frontiers in Pediatrics | www.frontiersin.org
Edited by: 
Claudio Pignata, 
University of Naples Federico II, Italy
Reviewed by: 
Lisa Renee Forbes, 
Baylor College of Medicine, USA  
Raffaele Badolato, 
University of Brescia, Italy
*Correspondence:
Kristina De Paris 
abelk@med.unc.edu
Specialty section: 
This article was submitted to 
Pediatric Immunology, 







Nieves J, Bernhardt J, Tuck R, 
Choudhary N, Mengual M, 
Mollan KR, Hudgens MG, Peter-
Wohl S and De Paris K (2017) 
Increasing JAK/STAT Signaling 
Function of Infant CD4+ T Cells during 
the First Year of Life. 
Front. Pediatr. 5:15. 
doi: 10.3389/fped.2017.00015
increasing JaK/sTaT signaling 
Function of infant cD4+ T cells 
during the First Year of life
Myra Grace dela Peña-Ponce1, Jennifer Rodriguez-Nieves1, Janice Bernhardt2, 
Ryan Tuck1, Neelima Choudhary1, Michael Mengual1, Katie R. Mollan3, 
Michael G. Hudgens4, Sigal Peter-Wohl2 and Kristina De Paris1*
1 Department of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA, 
2 Division of Neonatal Perinatal Medicine, Department of Pediatrics, School of Medicine, University of North Carolina, Chapel 
Hill, NC, USA, 3 Lineberger Cancer Center, Center for AIDS Research, University of North Carolina, Chapel Hill, NC, USA, 
4 Gillings School of Global Public Health, Center for AIDS Research, University of North Carolina, Chapel Hill, NC, USA
Most infant deaths occur in the first year of life. Yet, our knowledge of immune 
development during this period is scarce and derived from cord blood (CB) only. To 
more effectively combat pediatric diseases, a deeper understanding of the kinetics 
and the factors that regulate the maturation of immune functions in early life is needed. 
Increased disease susceptibility of infants is generally attributed to T helper 2-biased 
immune responses. The differentiation of CD4+ T cells along a specific T helper cell 
lineage is dependent on the pathogen type, and on costimulatory and cytokine signals 
provided by antigen-presenting cells. Cytokines also regulate many other aspects of the 
host immune response. Therefore, toward the goal of increasing our knowledge of early 
immune development, we defined the temporal development of the Janus kinase (JAK)/
signal transducers and activators of transcription (STAT) signaling function of CD4+ T cells 
using cross-sectional blood samples from healthy infants ages 0 (birth) to 14 months. 
We specifically focused on cytokines important in T cell differentiation (IFN-γ, IL-12, and 
IL-4) or in T cell survival and expansion (IL-2 and IL-7) in infant CD4+ T cells. Independent 
of the cytokine tested, JAK/STAT signaling in infant compared to adult CD4+ T cells was 
impaired at birth, but increased during the first year, with the most pronounced changes 
occurring in the first 6 months. The relative change in JAK/STAT signaling of infant CD4+ 
T cells with age was distinct for each cytokine tested. Thus, while about 60% of CB 
CD4+ T cells could efficiently activate STAT6 in response to IL-4, less than 5% of CB 
CD4+ T cells were able to activate the JAK/STAT pathway in response to IFN-γ, IL-12 
or IL-2. By 4–6 months of age, the activation of the cytokine-specific STAT molecules 
was comparable to adults in response to IL-4 and IFN-γ, while IL-2- and IL-12-induced 
STAT activation remained below adult levels even at 1 year. These results suggest that 
common developmental and cytokine-specific factors regulate the maturation of the 
JAK/STAT signaling function in CD4+ T cells during the first year of life.
Keywords: infant cD4+ T cell development, cytokines, JaK/sTaT signaling, sTaT activation, age-dependent 
changes
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inTrODUcTiOn
Every day, 17,000 children under the age of 5 years die with close 
to 50% of these deaths being caused by infectious diseases (1). 
Most infant deaths occur in the first year of life (1), at a time when 
the infant has to simultaneously acquire the ability to tolerate 
normal commensal flora and to recognize pathogenic stimuli. To 
adapt and overcome this challenge, the infant immune response is 
qualitatively distinct from that of adults. Yet, most of our knowl-
edge of infant immunity is derived from CB analysis only. Thus, 
an important gap remains in our understanding of the kinetics 
and factors that drive and regulate the functional maturation of 
infant immune cells postnatally.
The development of the infant’s immune system is shaped by 
many different factors that range from genetic predispositions 
to nutrition, pathogen exposure, environmental stimuli, and 
others [reviewed in Ref. (2)]. It would be an insurmountable 
task to address all these factors adequately in a single study. The 
current study focused on CD4+ T cells because they play a key 
role in innate, in cellular, and in humoral adaptive immunity by 
secreting cytokines that (i) activate monocytes/macrophages and 
dendritic cells, (ii) promote effector function of CD8+ T cells, 
and (iii) influence antibody maturation and isotype switching 
(3–10). Increased susceptibility and severity of infectious diseases 
in infants has been attributed to impaired CD4+ T helper (Th) 1 
responses. The bias of infant CD4+ T cells toward T helper 2 (Th2) 
responses was suggested more than 25 years ago in mice (11), and 
human studies confirmed reduced IFN-γ production by infant 
CD4+ T cells (12–15).
The underlying immune mechanisms that contribute to the 
infant’s Th2 bias have only recently been discovered. Cytokines 
play a major role in deciding the fate of naïve CD4+ T cells 
toward the development of a specific Th cell lineage (16–21). The 
production of the Th1-defining cytokine IFN-γ by CD4+ T cells 
is critically dependent on IL-12 (22–24). However, not only do 
infant antigen-presenting cells produce less IL-12 than adults 
(12, 14, 25–29), naïve CD4+ T cells, that represent the majority of 
neonatal T cells, lack the expression of the IL-12Rβ2 (30–33). The 
preferential induction of IL-4, the prototype Th2 cytokine, versus 
IFN-γ in infant CD4+ T cells is further regulated by epigenetic 
modulations. Thus, the IL-12p35 gene is in a repressive chroma-
tin state in infant dendritic cells (34, 35), and while the promoter 
of IFN-γ is hypermethylated in infant compared to adult CD4+ 
T cells (36, 37), gene loci associated with Th2 cytokines, such as 
IL-13, are hypomethylated (38).
In addition to Th cell differentiation, cytokines regulate many 
other immune processes (17, 39–45). Cytokines encompass a 
large group of diverse soluble biological mediators that can act 
in an autocrine, paracrine, or endocrine fashion to exert their 
functions. Aberrations in cytokine signaling and/or gene defi-
ciencies have been associated with serious clinical outcomes, such 
as severe immunodeficiency (46, 47), inflammatory immune 
disorders (48), and altered lymphopoiesis (49). The importance 
of cytokine signaling in host immunity is further underlined 
by the fact that several viruses have evolved to inhibit specific 
components of cytokine signaling pathways to limit the induction 
of antiviral immunity (50, 51).
Cytokines mediate their specific function through the activa-
tion of distinct tyrosine kinases after receptor ligation. Cytokines 
binding to their receptors cause receptor dimerization and 
activation of Janus (JAK) kinases that can then recruit specific 
transcription factors, the signal transducers and activators of 
transcription (STAT) (52, 53). This signaling pathway was first 
described in response to interferons (53). There are four members 
in the JAK kinase family and seven mammalian STATs. Therefore, 
the specificity of cytokine function is achieved in a stepwise fash-
ion, through activation of distinct JAK kinases, the subsequent 
formation of specific homo- or heterodimers of activated STATs, 
and finally the regulated expression of distinct genes upon trans-
location of the STAT molecules to the nucleus (52, 53).
Considering the key role of cytokines in many aspect of host 
immunity and disease, the current study defined the temporal 
development of JAK/STAT signaling function of CD4+ T cells in 
response to cytokines important in Th cell differentiation (IFN-γ, 
IL-12, and IL-4) and in T cell expansion (IL-2 and IL-7) using 
cross-sectional blood samples from healthy infants ages 0 (birth) 
to 14 months. Our analysis was focused on key components of the 
JAK/STAT signaling pathway: (i) cytokine receptor expression, 
(ii) JAK activation, and (iii) the activation of cytokine-specific 
STAT molecules. IFN-γ and IL-12 signal through JAK1/JAK2 and 
JAK2/Tyk2, respectively, while IL-4, IL-2, and IL-7, as members 
of the common gamma chain (γc) cytokine family, all signal 
through JAK1 and JAK3 [reviewed in Ref. (54)]. As the JAK1 
kinase is common to all of the signaling pathways, the activation 
of specific STAT molecules by distinct cytokines represented a 
key aspect of our analysis. Thus, to assess age-dependent changes 
in IFN-γ, IL-12, or IL-4-specific signaling, we measured the 
activation of STAT1, STAT4, or STAT6, respectively. To assess 
IL-2- and IL-7-mediated cytokine signaling, STAT5 activation 
was measured (54). Furthermore, to address a potential role of 
JAK/STAT signaling in Th-2 biased infant immune responses, 
we compared the activation of JAK2 and STAT1 by IFN-γ to the 
activation of JAK3 and STAT6 in response to IL-4.
MaTerials anD MeThODs
human subjects
Study subjects were recruited from the University of North 
Carolina, Chapel Hill (UNC-CH) and the NC Children’s Hospital. 
CB samples from full-term infants were collected immediately 
after birth or obtained from the Carolinas Cord Blood Bank. 
Direct capillary or venous blood samples (0.5–3.0  mL) from 
infants age 2 weeks to 14 months were collected by nursing or 
phlebotomy personnel during routine physician visits. The 
infants consisted of similar numbers of males and females. The 
exact number of infants per age group is listed in Table 1; we had 
70 CB samples, 35 samples from infants between the ages of 1 and 
9 months and 64 samples from 1 year olds (10–14 months). The 
large number of infants (n = 169) was required because limited 
blood volumes (0.5–2.0 mL) from infants age 2 weeks to 1 year 
restricted the number of assays and parameters that could be 
analyzed. The infant participants were recruited from the North 
Carolina population that consists of about 46% Caucasians, 46% 
Table 1 | study population.
age no. of subjects by sex
Male Female Unknown Total
Birth 24 24 22a 70
1–3 months 3 7 0 10
4–6 months 6 11 2 19
7–9 months 2 4 0 6
10–14 months 39 24 1 64
Total 74 70 25 169
aCord blood samples obtained from the Carolinas Cord Blood Bank.
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African-Americans, and 8% other groups, and within the ethnic 
categories, 10% represent Hispanics.
Exclusion criteria included HIV-positive status of the mother, 
known in utero infections, treatment of the mother with immu-
nosuppressive drugs, diagnosis of mother or child with immuno-
suppressive disorder, life-threatening malformations of the infant 
or life expectancy <6  months. Infant blood samples were also 
excluded if the infant had a bleeding disorder or had a chronic 
infection. The Virology, Immunology, and Microbiology Core 
of the UNC Center for AIDS Research provided blood samples 
from healthy adults. Age, sex, and race of the adult donors were 
unknown. The study was approved by the UNC-CH Institutional 
Review Board, and informed parental consent was obtained. 
Institutional guidelines strictly adhere to the World Medical 
Association’s Declaration of Helsinki.
sample Processing
Cord blood from full-term infants was collected into CB col-
lection bags containing CPD anticoagulant, whereas all other 
blood samples were collected into EDTA-containing blood 
tubes. Blood samples were processed within 24 h. Whole blood 
was used for Phosflow™ analysis of JAK2 and STAT proteins; 
for all other assays, peripheral blood mononuclear cells (PBMCs) 
were isolated by gradient density separation using Lymphocyte 
Separation Medium (MP Biomedicals, OH) as described (55, 56).
cD4+ T cell enrichment
CD4+ T cells were enriched by magnetic bead separation using 
the CD4+ T cell enrichment Kit from Stemcell Technologies 
(Vancouver, BC, Canada) according to the manufacturer’s 
instructions. The purity of CD4+ T cell populations was confirmed 
by flow cytometry and exceeded 96%.
cytokine receptor expression
Peripheral blood mononuclear cells were stained with CD3 
(SP34-2)-Pacific Blue, CD4 (L200)-PerCPCy5.5, CD8 (RPA-T8)-
Alexa Fluor700, CD45RA (5H9)-FITC, and CCR7 (3D12)-PeCy7 
to determine naïve [T(N): CD45RA+CCR7+], central memory 
[T(CM): CD45RA−CCR7+], and effector/effector memory cell 
[T(Eff/EM), CD45RA±CCR7−] T cell populations. All antibodies, 
unless noted otherwise, were purchased from BD Biosciences (San 
Jose, CA, USA). The expression of cytokine receptors on CD4+T 
cells was quantitated using PE-labeled antibodies: IFN-γR1 
(CD119-GIR-208), IFN-γR2 (2HUB-159, Biolegend, San Diego, 
CA, USA), IL-4Rα (hIL4R-M57), IL-2Rα (CD25-clone-4E3, 
Miltenyi Biotec, Auburn, CA, USA), or IL-2Rβ (CD122-clone-
Mikβ). Cytokine receptor expression is reported as percentage 
of CD4+ T cell populations or quantitated on a per cell basis 
using a standard curve generated with Quantibrite PE beads 
(BD Biosciences). The staining protocol was performed at 4°C. 
Samples were acquired on a LSRII instrument (BD Biosciences) 
by collecting a minimum of 300,000 events. The flow cytometry 
data were analyzed using FlowJo Software (Tree Star, Ashland, 
OR, USA), version 9.8. Antibodies were titrated prior to use and 
gating was based on Fluorescence Minus One (FMO) and isotype 
antibody controls.
Phosflow™ analysis
Phosflow™ analysis was performed to measure the activation of 
JAK2 after IFN-γ stimulation or the activation of STAT proteins 
according to the manufacturer’s protocols (BD Biosciences) 
using Perm Buffer III (CD4+ T cells) or Perm Buffer IV (NK 
cells). Although most JAK and STAT molecules contain multiple 
tyrosine and/or serine phosphorylation sites, the analysis was 
limited to a single phosphorylation site. Briefly, 300–400 µL of 
whole blood was treated for 10 min with 10 µg/mL of human 
recombinant IFN-γ (Miltenyi Biotec) and samples were then 
stained with antibodies to total JAK2 or with antibodies to 
phosphorylated JAK2 (Tyr1008; clone D4A8, Cell Signaling 
Technology, Danvers, MA, USA). Phospho-JAK2 (pJAK2) was 
detected with anti-rabbit IgG (H + L), F(ab’)2 Fragment (Alexa 
Fluor 647, Cell Signaling Technology). To detect the phospho-
rylation of specific STAT proteins after stimulation with IFN-γ 
IL-4, IL-2, or IL-7, whole blood was incubated for 15 min with 
10  µg/mL of recombinant IFN-γ, 0.1  µg/mL of recombinant 
IL-4 (R&D, Minneapolis, MN, USA) or 0.1  µg/mL human 
IL-2 or IL-7 (Miltenyi Biotec), respectively, and subsequently 
stained for phosphorylated STAT-1 (Tyr 701; clone 58D6, Cell 
Signaling Technology), STAT6 (Y641; clone pY641) or STAT5 
(Y694; clone pY694, both BD Biosciences), respectively. Non-
phosphorylated STAT1, STAT6, or STAT5 proteins were meas-
ured in parallel. Unstimulated whole blood served as negative 
control. STAT4 phosphorylation (pSTAT4 Y693) was measured 
using the same protocol, except that PBMCs were stimulated for 
45 min with IL-12 (75 ng/mL) in serum-free RPMI 1640 media. 
To distinguish CD4+ T cells with different antigen experience, 
blood samples were costained with CD3 (SP34-2)-PeCy7, CD4 
(L200)-PerCPCy5.5, and CD27 (L128)-PE, and naïve, central 
memory, and effector/effector memory populations were 
defined as being CD27+, CD27low, or CD27−, respectively (57). 
Cytokine concentrations and incubation times were determined 
in preliminary experiments (data not shown). Samples were 
acquired on a LSRII instrument analyzed with FlowJo Software. 
Cells positive for JAK2 or STAT phosphorylation are reported 
as percentage of CD4+ T cells after subtracting the values from 
the untreated samples. Antibodies were titrated prior to use 
and gating was based on FMO and isotype antibody controls. 
In addition, a subset of samples was analyzed on the Amnis® 
ImageStreamX instrument according to the manufacturer’s 
protocol.
4dela Peña-Ponce et al. Infant CD4+ T Cell Cytokine Signaling
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 15
JaK3 activation
The phosphorylation of JAK3 in response to stimulation 
with IL-4 or IL-2 was measured by Western blot. CD4+ T 
cells were enriched as described above and either stimulated 
immediately with IL-4 or IL-2 or preactivated for 2  days 
prior to cytokine stimulation. For the latter, CD4+ T cells 
were stimulated at a concentration of 2–4 × 106 cells/mL with 
plate-bound anti-CD3 (10 µg/mL; clone SP34-2), precoated 
overnight in a 24-well plate, and cultured at 37°C and 5% 
CO2. Controls were set up in parallel with media only. After 
48  h, to activate JAK3, CD4+ T cells were stimulated for 
5  min with 0.1  µg/mL recombinant human IL-4 or IL-2 at 
37°C in a water-bath followed by a 5-min centrifugation at 
300 × g (total stimulation time: 10 min). Cells were lysed with 
100 µL of Blue Loading Pack (Cell Signaling Technology) per 
4 × 106 cells. Protein concentrations were determined using 
the Pierce 660  nm Assay (Thermo Scientific, Rockford, IL, 
USA). Samples were loaded onto 8% Novex® Tris-Glycine 
gels (Novex®, Life Technologies, NY, USA). The XCell 
SureLock™ Mini Cell was used for electrophoresis in 
Novex® Tris-Glycine SDS running buffer and for subsequent 
transfer using Novex® Tris-Glycine transfer buffer. Transfer 
PVDF membranes were obtained from Bio-Rad Laboratories 
(Hercules, CA, USA). All detection antibodies and reagents 
were obtained from Cell Signaling Technology unless 
noted otherwise. To determine JAK3 phosphorylation, the 
membranes were incubated with phospho-JAK3 antibody 
(Tyr980/981; clone D44E3; 1:1,000 dilution) in 1× TBST 
overnight, stripped using Restore Plus Western blot (Pierce/
Thermo Scientific, Rockville, IL, USA) and re-probed for 
non-phosphorylated JAK3 (clone D1H3; 1:1,000 dilution:) 
and beta (β)-Actin (clone 13E5; 1:50,000 dilution) as loading 
control. The membranes were then incubated with secondary 
anti-Rabbit IgG HRP-linked antibody at a dilution of 1:2,000 
and developed using the Amersham™ ECL Prime Western 
Blotting Detection Reagent (GE Healthcare Life Sciences, 
Pittsburgh, PA, USA). Images were captured using the Bio-
Rad ChemiDoc MP System and densitometric measurements 
were obtained using the Image Lab Software Version 5.2.1. 
Protein sizes were verified based on the NuPage HiMark 
Prestained Protein Standard (Life Technologies, Grand 
Island, NY, USA).
statistical analysis
Data were analyzed using GraphPad Prism Software (Version 
6, 2014; La Jolla, CA, USA). Continuous measurements 
were compared between independent age groups using non-
parametric Mann–Whitney tests. Statistical comparisons were 
only performed if the sample size was n ≥ 4 in both age groups. 
Associations between continuous variables was estimated using 
non-parametric Spearman rank correlation. To visualize the 
age-dependent changes in STAT activation in response to IL-4, 
IFN-γ, and IL-2, a LOESS trend curve was generated with a 
smooth parameter of 0.5. Only statistically significant p-values 
are shown in the figures. A 0.05 significance level was used with 
no adjustment for multiple hypothesis testing.
resUlTs
cytokine receptor expression on infant 
cD4+ T cells
Cytokine receptor expression was evaluated both by quantifying 
the number of receptors per CD4+ T cell and by determining the 
percentage of CD4+ T cells expressing each cytokine receptor. 
Two main comparisons were performed. First, we determined 
whether there was a significant change in cytokine receptor 
expression from birth to 1 year of age. Second, we tested whether 
the expression of cytokine receptors differed between 1-year-old 
infants and adults. These comparisons were conducted both for 
total CD4+ T cells and for CD4+ T cell subsets. The analysis of 
CD4+ T cells according to their phenotypic characterization 
as naïve [T(N); CD45RA+CCR7+], central memory [T(CM); 
CD45RA−CCR7+], or effector memory/effector [T(EM/Eff); 
CD45RA±CCR7−] CD4+ T cells was important because the 
majority of infant peripheral blood CD4+ T cells represent naïve 
CD4+ T cells and the relative frequencies of these CD4+ T cell 
population change with age and pathogen exposure. Thus, this 
analysis was necessary to accurately evaluate age-related differ-
ences in infant CD4+ T cells from birth to 1  year, and equally 
critical for the comparison of infant and adult CD4+ T cell 
parameters.
Cord blood CD4+ T cells expressed significantly more IL-4Rα 
molecules per CD4+ T cell than adults (Table 2). Although there 
was an age-dependent decline in median IL-4Rα numbers/CD4+ 
T cell comparing birth to 1 year, these differences were not sta-
tistically significant. The percentage of IL-4Rα+CD4+ T cells also 
did not vary substantially with age (Table 3). To initiate signaling 
upon IL-4 binding, the IL-4Rα chain dimerizes with the common 
γ-chain (γc); we did, however, not measure the common γ-chain, 
because previous studies have already shown that it is expressed 
at lower levels in infants (58).
The IFN-γ receptor consists of the IFN-γR1, promoting IFN-
γ binding, and the IFN-γR2 that mediates signaling to the JAK 
kinases. The number of IFN-γR1 molecules per CD4+ T cell did 
not significantly differ between birth and 1 year (Table 2). CD4+ 
T cells in CB and in blood from 1-year-old infants expressed 
significantly higher numbers of IFN-γR1/CD4+ T cell than 
adults (Table 2; Figure 1A). In contrast, the percentage of CD4+ 
T cells expressing IFN-γR1 increased from birth to 1 year, and 
even at 1  year, the percentage of IFN-γR1+CD4+ T cells was 
significantly lower compared to adults (Table 3, Figure 1A). This 
difference was especially pronounced in the subset of effector 
memory/effector CD4+ T cells (Table 3; Figure 1B). We did not 
observe significant changes in total expression levels of IFN-γR2 
(Table  2), and although the frequencies of naïve and effector 
memory/effector IFN-γR2 CD4+ T cells seemed to decrease in 
the first year, the biological significance of the changes is ques-
tionable given their very low frequencies (Table  3). Note that 
the relatively low frequencies of IFN-γR1 or IFN-γR2 CD4+ T 
cells in infants were not the result of poor staining, as IFN-γR-
positive B cells could be easily enumerated in the same samples 
(Figure 1C). The analysis of the ratio of relative expression levels 
of IL-4Rα to IFN-γR1 or IL-4Rα to IFN-γR2 on infant CD4+ T 
Table 2 | cytokine receptor expression.
cytokine 
receptor




birth 1–3 months 4–6 months 7–9 months 10–14 months adult
IL-4Rα CD4+ T 409 (61–1,026) 407 (300–412) 311 (271–429) 303 (271–451) 286 (201–662) 278 (179–368) NS* NS
CD4+ T (N) 440 (59–1,106) 433 (350–434) 381 (368–505) 314 (273–380) 283 (196–996) 281 (210–423) NS NS
CD4+ T (CM) 324 (57–910) 360 (252–362) 247 (230–350) 275 (250–459) 287 (196–331) 265 (172–391) NS NS
CD4+ T (EM/Eff) 449 (83–1,040) 391 (315–568) 450 (265–567) 516 (397–725) 333 (175–395) 304 (200–371) NS NS
IFN-γR1 CD4+ T 1,118 (138–4,738) 2,019 (1,018–5,247) 972 (785–1,119) n.d.** 834 (627–1,388) 653 (390–1,824) NS p = 0.0057
CD4+ T (N) 1,202 (137–3,804) 2,350 (1,172–13,874) 1,387 (885–1,638) n.d. 944 (668–2,756) 872 (430–3,293) NS NS
CD4+ T (CM) 1,276 (140–5,039) 2,477 (1,015–4,238) 883 (783–946) n.d. 776 (599–1,159) 718 (364–2,063) NS NS
CD4+ T (EM/Eff) 783 (133–12,727) 926 (777–1,687) 708 (608–817) n.d. 640 (594–909) 568 (392–1,792) NS NS
IFN-γR2 CD4+ T 686 (105–1,641) 974 (894–1,072) 1,527 (813–1,940) n.d. 630 (299–1,062) 635 (271–2,018) NS NS
CD4+ T (N) 750 (101–2,102) 1,581 (1,155–1,826) 2,525 (1,210–3,842) n.d. 860 (413–1,367) 890 (332–2,213) NS NS
CD4+ T (CM) 564 (71–1,696) 688 (627–906) 853 (551–965) n.d. 451 (253–856) 507 (223–2,573) NS NS
CD4+ T (EM/Eff) 624 (151–7,201) 995 (473–1,379) 806 (548–1,547) n.d. 684 (355–3,409) 584 (289–1,873) NS NS
IL-2Rα CD4+ T 696 (214–2,420) 1,548 (1,369–1,606) 1,052 (621–1,780) 1,446 (1,032–1,633) 1,121 (807–1,815) 501 (200–1,439) p = 0.0074 p = 0.0015
CD4+ T (N) 610 (158–3,166) 1,836 (1,407–1,912) 1,382 (678–2,821) 2,005 (1,782–2,155) 1,575 (1,019–2,497) 420 (238–1,170) p = 0.0006 p < 0.0001
CD4+ T (CM) 667 (232–2,330) 1,345 (1,293–1,349) 975 (696–1,335) 1,266 (869–1,356) 981 (607–1,467) 452 (183–1,176) p = 0.0378 p = 0.0010
CD4+ T (EM/Eff) 853 (452–2,702) 1,730 (1,365–1,815) 1,122 (613–1,661) 1,469 (947–1,699) 1,176 (911–2,119) 659 (220–1,827) NS p = 0.0022
IL-2Rβ CD4+ T 338 (45–1,776) n.d. 410 (294–704) n.d. 289 (207–427) 266 (145–461) NS NS
CD4+ T (N) 444 (46–1,491) n.d. 436 (377–3,302) n.d. 300 (201–540) 340 (171–671) NS NS
CD4+ T (CM) 261 (52–3,329) n.d. 362 (270–393) n.d. 272 (203–383) 225 (134–457) NS NS
CD4+ T (EM/Eff) 344 (43–3,726) n.d. 338 (294–519) n.d. 280 (212–347) 265 (130–457) NS NS
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Table 3 | cytokine receptor expression.
cytokine 
receptor




birth 1–3 months 4–6 months 7–9 months 10–14 months adult
IL-4Rα CD4+ T 0.4 (0.1–3.8) 0.3 (0.1–0.3) 0.4 (0.2–0.4) 0.4 (0.3–0.6) 0.2 (0.1–4.0) 0.5 (0.1–1.2) NS* NS
CD4+ T (N) 2.5 (0.2–61.3) 1.4 (0.2–4.8) 0.6 (0.6–0.7) 0.7 (0.6–0.8) 0.4 (0.1–23.8) 0.9 (0.2–4.2) NS NS
CD4+ T (CM) 0.2 (0.0–0.7) 0.1 (0.1–0.2) 0.3 (0.1–0.3) 0.3 (0.2–0.5) 0.2 (0.1–4.8) 0.4 (0.1–1.7) NS NS
CD4+ T (EM/Eff) 0.6 (0.1–27.0) 0.1 (0.1–0.2) 0.1 (0.1–0.3) 0.6 (0.1–0.7) 0.2 (0.0–0.6) 0.2 (0.0–0.6) p = 0.0114 NS
IFN-γR1 CD4+ T 1.1 (0.2–3.9) 1.4 (0.8–2.5) 1.9 (1.3–3.0) n.d.** 1.4 (0.5–3.3) 4.3 (1.3–10.0) NS p < 0.0001
CD4+ T (N) 2.1 (0.3–19.1) 4.4 (0.8–5.6) 2.1 (1.7–2.8) n.d. 1.5 (0.4–2.5) 0.8 (0.3–2.7) NS NS
CD4+ T (CM) 0.8 (0.1–3.4) 1.0 (0.5–1.8) 1.6 (1.1–2.9) n.d. 1.2 (0.4–2.3) 1.1 (0.3–5.6) NS NS
CD4+ T (EM/Eff) 3.4 (0.6–18.7) 3.8 (2.9–3.8) 5.9 (1.8–6.8) n.d. 6.3 (1.7–9.3) 12.6 (3.9–31.7) NS p < 0.0001
IFNγR2 CD4+ T 0.5 (0.1–7.0) 0.6 (0.4–0.7) 0.5 (0.3–0.7) n.d. 0.5 (0.2–0.8) 0.2 (0.1–1.9) NS NS
CD4+ T (N) 3.1 (0.2–53.6) n.d. 2.5 (0.6–5.0) n.d. 0.4 (0.1–1.0) 0.3 (0.1–2.3) p = 0.0292 NS
CD4+ T (CM) 0.2 (0.0–3.6) n.d. 0.4 (0.1–0.5) n.d. 0.3 (0.1–0.8) 0.1 (0.0–1.0) NS NS
CD4+ T (EM/Eff) 1.2 (0.0–14.7) n.d. 0.4 (0.1–0.5) n.d. 0.2 (0.0–0.7) 0.2 (0.0–4.2) p = 0.0053 NS
IL-2Rα CD4+ T 4.1 (1.2–16.2) 11.3 (6.9–14.7) 9.8 (7.1–14.0) 9.6 (8.6–11.7) 9.6 (7.9–13.8) 30.6 (16.2–41.4) p = 0.0006 p < 0.0001
CD4+ T (N) 3.7 (0.5–65.2) 12.6 (5.4–15.6) 8.3 (4.4–16.4) 9.1 (9.0–10.6) 7.4 (2.9–14.7) 9.7 (4.6–23.1) NS NS
CD4+ T (CM) 1.8 (0.3–14.9) 6.4 (5.2–11.6) 6.2 (4.7–10.6) 6.4 (4.0–7.1) 8.1 (5.3–10.3) 36.8 (21.2–53.8) p = 0.0016 p < 0.0001
CD4+ T (EM/Eff) 38.3 (0.2–87.5) 77.0 (44.4–82.5) 49.8 (29.5–66.5) 42.2 (34.0–52.0) 44.2 (36.8–58.3) 47.4 (27.3–76.4) NS NS
IL-2Rβ CD4+ T 0.5 (0.1–7.5) n.d. 0.2 (0.0–0.3) n.d. 0.4 (0.1–2.7) 0.9 (0.1–4.3) NS NS
CD4+ T (N) 0.6 (0.2–11.1) n.d. 0.2 (0.0–0.3) n.d. 0.2 (0.0–1.8) 0.2 (0.1–1.7) NS NS
CD4+ T (CM) 0.2 (0.0–1.4) n.d. 0.1 (0.0–0.2) n.d. 0.3 (0.1–2.2) 0.7 (0.1–4.4) NS NS
CD4+ T (EM/Eff) 3.0 (0.1–16.1) n.d. 0.7 (0.1–1.5) n.d. 1.9 (0.2–9.6) 1.8 (0.1–8.9) NS NS
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FigUre 1 | cytokine receptor expression in infants. (a) The changes in absolute numbers of IFN-γR1 on CD4+ T cells and the percentage of IFN-γ+ CD4+ 
T cells with age. Each symbol represents an individual infant (open triangle); adults are shown by black cross symbols. The p values indicate statistically significant 
differences between 10–14 months old infants and adults. (b) The percentage of IFN-γ+ CD4+ T cells in naïve [T(N)], central memory [T(CM)], and effector memory/
effector [T(EM/Eff)] CD4+ T cells of 10- to 14-month-old infants and adults. (c) A representative histogram of IFN-γR1-positive cells in an infant blood sample. Note 
that the majority of IFN-γR1-positive cells represent B cells. (D) The left graph shows the age-dependent increase in soluble CD25 (sCD25) plasma levels. The right 
graph illustrates the Spearman rank correlation between sCD25 plasma levels and IL-2Rα+CD4+ T cells using infants at birth and 1 year. Each symbol represents an 
individual infant, with infants at different ages being characterized by specific symbols: cord blood (CB): open triangle, 1–3 months: yellow diamonds, 4–6 months: 
orange circles, 7–9 months: red hexagons, 10–14 months (1 year): blue triangles. Horizontal lines represent median values. The differences in plasma sCD25 levels 
between CB and 1-year olds were determined by Mann–Whitney test.
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cells did not reveal changes that would support a switch from a 
more Th2-biased response at birth versus a more balanced Th2/
Th1 response at 1 year.
An analysis of the IL-2R was included because T cell expan-
sion is a critical step in T cell differentiation. The IL-2R consists 
of three distinct chains, the α, β, and γ-chain. The IL-2Rα 
chain (or CD25) is of special importance as it is a marker of 
regulatory T cells (Tregs), which occur in higher frequencies 
in infant compared to adult blood, but CD25 is also expressed 
on activated T cells that are more frequent in adult peripheral 
blood. Both, absolute numbers of IL-2Rα per CD4+ T cell and 
the percentage of IL-2Rα+CD4+ T cells were higher at 1 year 
of age than at birth (Tables  2 and 3; Figure  1D). At 1  year, 
the number of IL-2Rα molecules per CD4+ T cells exceeded 
that of adult CD4+ T cells (Table 2), whereas the percentage 
of IL-2Rα+CD4+ T cells was significantly lower compared 
to adults (Table  3). Whether or not these results reflected 
the dichotomy of the CD25 molecule as a marker of Treg or 
activated CD4+ T cells was not a focus of the study. However, 
soluble CD25 (sCD25) plasma levels were higher at 1 year com-
pared to CB (Figure 1D), and there was a significant positive 
correlation between plasma sCD25 levels and the percentage 
of IL-2Rα+CD4+ T cells (Figure  1D). Although these results 
were indicative of increasing activated CD4+ T cells with age, 
higher sCD25 plasma levels (Figure 1D) and IL-2Rα+CD4+ T 
cells (Table 3) were already increased by 1–3 months and did 
not further increase from 3 to 14 months.
The expression levels of IL-2Rβ did not differ between infant 
CD4+ T cells at birth and or at 1 year, or between CD4+ T cells of 
1-year-old infants and adults. We did not measure the expression 
of the common γ-chain (see above).
The results highlight that naïve, central memory, and effector 
memory CD4+ T cells show age-dependent differences in cytokine 
receptor expression that are likely to influence the functional 
capacity of these CD4+ T cell subsets.
il-4 signaling ability of infant cD4+ T cells
As the Th2-bias of infant CD4+ T cells is well documented, we 
hypothesized that CB CD4+ T cells would activate the JAK/
STAT signaling pathway in response to IL-4 as effectively as adult 
CD4+ T cells. Upon binding of IL-4 to its receptor, JAK1 and 
JAK3 will be activated by engaging the IL-4Rα or the common 
γ chain, respectively. As the common γ chain is also part of the 
IL-2 receptor, we chose to measure JAK3 activation to maximize 
the number of parameters that could be analyzed considering the 
small sample volumes available. The limited blood volumes for 
10- to 14-month-old infants also required that we pooled PBMCs 
from multiple infants (pool 1: n = 9; pool 2: n = 5) to enrich CD4+ 
T cells for Western blot analysis.
The protein levels of total JAK3 were comparable between 
CD4+ T cells isolated from CB, 1-year olds or adults (Figure 2A). 
With the caveat that exact frequencies of pJAK3+CD4+ T cells 
could not be quantified by Western blot, CD4+ T cells isolated 
from CB or 1-year-old infants were equally able to activate pJAK3 
in response to IL-4 (Figures 2B,C). Thus, densitometry analysis 
showed no statistically significant differences in the increase 
of median pJAK3 densities in IL-4 stimulated compared to 
unstimulated CD4+ T cells in CB (19-fold; range: 4.9- to 25.4-
fold), samples of 1 year olds (13-fold; range: 10.7- to 15.4-fold), 
and adults (2.5-fold; range: 2.2- to 11.6-fold).
The effective activation of pJAK3 by IL-4 in CB was confirmed 
by the fact that the downstream IL-4-specifc transcription factor 
STAT6 was activated in 64% (median value) of CB CD4+ T cells, 
although subject-to-subject variation at birth was high (range: 
14–99%; Figure 2D). Despite the seemingly potent induction of 
the JAK/STAT signaling pathway by IL-4 in CB, median frequen-
cies of pSTAT6+CD4+ T cells were lower compared to adults 
(93%; range: 60–98%). The activation of pSTAT6 significantly 
increased with age (Figure  2D), and by 4–6  months of age, 
pSTAT6 activation was comparable to 1-year-old infants and to 
adults (Figure 2D). The age-dependent increase in IL-4-induced 
pSTAT6 activation observed in the total CD4+ T cell populations 
appeared to be mainly reflective of changes in naive CD4+ T cells 
(Figure  2D). Although memory CD4+ T cells also responded 
with higher pSTAT6 activation by 4–6  months and at 1  year, 
pSTAT6 activation remained below [T(CM)] or within the lower 
range [T(EM/Eff)] of adult memory CD4+ T cells (Figure 2D). 
However, as naïve cells represented the majority of infant CD4+ T 
cells, the reduced pSTAT6 activation by infant memory cells was 
masked in the total CD4+ T cell population.
To test for the translocation of activated pSTAT6 to the 
nucleus, a critical event for downstream gene induction, we 
utilized Amnis® ImageStreamX analysis. CB and adult CD4+ 
T cells showed similar expression of unphosphorylated STAT6 
(Figure 3). Upon IL-4-stimulation, activated pSTAT6 was clearly 
detectable in the nucleus of CB CD4+ T cells, but the fluorescence 
intensity was slightly stronger in CD4+ T cells of an 8-month-old 
infant and in adult CD4+ T cells (Figure 3).
age-Dependent increase in iFn-γ-induced 
JaK/sTaT signaling
In contrast to JAK3 activation by IL-4, only a small fraction of 
CB CD4+ T cells induced JAK2 phosphorylation in response to 
IFN-γ stimulation (Figure 4A). The histograms in Figure 4B are 
representative for CB and adult CD4+ T cells and demonstrate 
that unstimulated CD4+ T cells in both age groups have similar 
low levels of pJAK2 and similar background level staining in 
FMO controls, but clearly differ in the levels of pJAK2 after IFN-
γ stimulation. However, by 1 year of age, pJAK2 activation was 
even higher than in adult CD4+ T cells (Figure 4A). To more spe-
cifically determine when infant CD4+ T cell acquired improved 
IFN-γ signaling capacity, we measured STAT1 phosphorylation 
in CD4+ T cells from birth to 1 year. As expected, the increase in 
pSTAT1 activation paralleled the observed increase in pJAK2+ 
CD4+ T cells (Figure  4C). In CB, only 1.3% (median; range: 
0.0–10.7%) CD4+ T cells activated pSTAT1 upon IFN-γ stimula-
tion (Figure  4D). Activation of pSTAT1 was already increased 
by 1–3  months of age (median: 26.1%) and by 4–6  months 
pSTAT1+CD4+ T cell frequencies were detected in about 40% 
CD4+ T cells (Figure 4D); representative histograms are shown 
in Figure S1 in Supplementary Material. Although there was a 
significant positive correlation between increasing infant age and 
higher frequencies of pSTAT1+CD4+ T cells, this relationship 
AD
B C
FigUre 2 | JaK/sTaT activation in infant cD4+ T cells in response to il-4. (a) Representative Western blot gel for total JAK3 (upper band; empty white 
arrow) and the β-actin control (lower band, empty arrow head) using CD4+ T cell protein lysates from cord blood samples, 10- to 14-month-old infants and adults 
stimulated with IL-4 or IL-2 in comparison to media (M) only. (b) Representative Western blot showing phosphorylated JAK3 (pJAK; black arrow). (c) Western blot 
gels were analyzed by densitometry to determine relative changes in JAK3 activation in media or IL-4 stimulated CD4+ T cells. (D) The graphs show the frequencies 
of pSTAT6+ cells in total CD4+ T cells and in naïve [T(N)], central memory [T(CM)], and effector memory/effector [T(EM/Eff)] CD4+ T cell populations of at birth 
(n = 33), infants aged 4–6 (n = 6) and 10–14 (n = 11) months. The gray area in each graph represents the median frequencies (middle line) of pSTAT6+ CD4+ T cells 
in adults (n = 25), with the lower and upper line corresponding to the 25th and 75th percentile. Each symbol represents an individual subject, with the exception of 
(b): the samples for 10- to 14-month-old infants represent pools of nine or five subjects each. Statistical significant differences between two age groups were 
determined by non-parametric Mann–Whitney test.
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did not appear to be linear (Figure 4D). In fact, IFN-γ-induced 
pSTAT1 activation seemed to plateau at about 6 months of age 
(Figure 4D; Table S1 and Figure S2 in Supplementary Material). 
As was shown for total STAT6 expression, unphosphorylated 
STAT1 could be detected in both CB and adult CD4+ T cells 
(Figure  4E). However, consistent with the age-dependent 
increase in pSTAT1 activation, activated pSTAT1 was localized 
mainly in the cytoplasm in CB CD4+ T cells, whereas in samples 
from 6-month-old infants pSTAT1 was clearly detectable in the 
nucleus (Figure 4E).
Compared to only a 1.4-fold increase in median frequencies 
of pSTAT6+CD4+ T cells from birth (63.8%) to 1 year (90.6%), 
median frequencies of pSTAT1+CD4+ T cells increased 30-fold in 
the first year (birth: 1.3%; 1 year: 38.0%) (Figure 5A). Furthermore, 
in samples for which sufficient blood volume was available to test 
both IL-4 and IFN-γ-induced JAK/STAT signaling, we observed 
a more than 10-fold increase in the ratio of pSTAT1:pSTAT6 from 
0.04 (median; range: 0.0–0.2) at birth to 0.5 (range: 0.4–0.9) at 
1  year (Figure  5B). Whether or not these findings have direct 
implications for CD4+ Th cell differentiation, was outside the 
scope of the current study. To further probe CB CD4+ T cells 
for reduced signaling function in response to Th1-promoting 
cytokines, we tested whether STAT4 phosphorylation after 
in vitro IL-12 stimulation was also reduced. Indeed, only 0.42% 
(median value; range: 0.0–4.2%) CB CD4+ T cells responded 
with STAT4 phosphorylation (Figure 6A). Despite higher IL-12 
signaling ability of CD4+ T cells in 1-year-old infants, median 
frequencies of pSTAT4+CD4+ T cells still accounted for <1% in 
10- to 14-month-old infants (range: 0.1–1.7%) and remained 
significantly lower compared to pSTAT4+ frequencies in adult 
FigUre 3 | amnis®-imagestreamX analysis of sTaT6 activation. The images are representative examples of whole blood samples that were untreated (left 
panels) or stimulated with IL-4 for 15 min (right panels) and then stained and analyzed for total (unphosphorylated) STAT6 and activated pSTAT6. Each image row 
shows a single cell labeled with CD3 (blue), CD4 (pink), unphosphorylated STAT 6 (yellow), or phosphorylated STAT6 (pSTAT6; green). The first two rows represent 
examples of cord blood (CB) stained with STAT 6 or pSTAT6; followed by an 8-month old infant blood sample, and one adult donor blood. Channel 1 (“Ch1”) shows 
the brightfield image of the cell in relation to the 10-μm size marker.
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CD4+ T cells (median: 3.3%; range: 0.2–18.2%) (Figure  6A). 
Consistent with this result, few CD4+ T cells with nuclear pSTAT4 
localization could be detected in 1-year-old infants (Figure 6B). 
In addition, it appeared that the nuclear translocation might have 
been less efficient compared to nuclear localization of pSTAT6 
or pSTAT1 in CD4+ T cells of 1-year-old infants stimulated with 
IL-4 or IFN-γ, respectively (Figure 6B). However, the tools for a 
more quantitative protein analysis of the Amnis®ImageStreamX 
data were not available.
Considering that the IL-12Rβ2 chain is not expressed on 
naive CD4+ T cells (59, 60), we compared in pSTAT4+CD4+ 
T cell frequencies in memory CD4+ T cells of different age 
groups. Despite the low frequencies of CD4+ T cells that can be 
phenotypically characterized as T(CM) or T(EM/Eff) CD4+ T 
cells in CB, about 1 and 4%, respectively, could activate pSTAT4. 
By 1 year, the functional capacity of T(EM/Eff) CD4+ T cells to 
signal in response to IL12 was equivalent to adult T(EM/Eff) 
CD4+ T cells (Figures 6C,D), but the low frequencies of differ-
entiated infant CD4+ T cells likely prevented the detection of this 
response within the total CD4+ T cell population (Figure 6A). 
Despite higher frequencies of memory CD4+ T cells in adults, 
IL-12Rβ2 expression is relatively low within the total CD4+ T cell 
population (Figure S3 in Supplementary Material). In contrast, 
NK cells (CD3−CD14−CD19−CD56+), even in infants, show more 
pronounced expression of IL-12Rβ2 (Figure S3 in Supplementary 
Material), with IL-12Rβ2 expression being highest on CD16+ NK 
cell subsets (Figure S3 in Supplementary Material).
JaK/sTaT signaling by infant cD4+ T cells 
in response to the γ chain cytokines il-2 
and il-7
IL-2 is a key cytokine promoting the proliferation and expansion 
of CD4+ T cells. As pointed out above, IL-2 signals through the 
common γ chain of the IL-2R and activates the JAK3 kinase. 
The activation of pJAK3 by IL-2 appeared to be comparable in 
CD4+ T cells from CB, blood of 1-year-old infants and adults 
(Figure  7A; see Figure  2A for controls). However, because we 
could not quantitate the exact number of pJAK3+CD4+ T cells 
by Western blot (Figure 7A), we measured the activation of the 
IL-2 specific transcription factor STAT5, downstream of JAK3. 
This analysis showed that frequencies of pSTAT5+CD4+ T cells 
were positively correlated (p  <  0.0001) with increasing age 
between birth and 1 year (Figure 7B). However, even at 1 year, 
median pSTAT5+CD4+ T cell frequencies (36%; range: 25–51%) 
remained significantly lower compared adults (median: 69%; 
range: 44–80%) (Figure 6B).
To determine whether this effect was specific for IL-2, we 
tested whether JAK/STAT signaling to the related common 
γ-chain cytokine IL-7, that also promotes proliferation, was 
impaired in infants as well. Compared to <1% median fre-
quencies of pSTAT5+ CD4+ T cells activated by IL-2 in CB, 
IL-7 induced about 19% (range: 0.3–73.2%) pSTAT5+CD4+ T 
cells (Figure 7C). IL-7-induced frequencies of pSTAT5+CD4+ 
T cells increased to 72% (range: 62.1–87.3%) by 4–6 months 
and reached 90% (range: 45.2–95.5%) by 1  year, levels com-
parable to those achieved in adults (median: 93.3%; range: 
83.0–97.6%) (Figure  7C). The differential signaling capacity 
of infant CD4+ T cells to IL-2 or IL-7 was further supported 
by image analysis of blood samples from 6-month-old infants 
(Figure  7D). Although we could consistently detect pSTAT5 
in the nucleus of samples stimulated with IL-7, activation 
and nuclear translocation of pSTAT5 in response to IL-2 was 
 variable (Figure 7E).
The difference in IL-2 versus IL-7 signaling was mainly due 
to differential activation of naïve CD4+ T cells (Figures 8A,B). 
At 1  year, pSTAT5+ frequencies within the naïve CD4+ T cell 
population were still significantly lower (p < 0.0001) compared 
to adults after IL-2 stimulation, whereas IL-7-induced pSTAT5+ 
CD4+ T(N) cell frequencies were comparable between 1-year olds 
FigUre 4 | iFn-γ-induced JaK/sTaT signaling. (a) The percentages of pJAK2+CD4+ T cells in cord blood (CB, n = 10), 4- to 6-month-old (n = 3), and 10- to 
14-month-old (n = 10) infants. Median frequencies of adult (n = 12) pJAK2+CD4+ T cells with the 25th and 75th percentile are indicated by the gray shaded area. (b) 
Representative pJAK2 histograms from a CB sample and an adult blood donor. Note that baseline pJAK2 levels are similar in CB and adult blood, and in IFN-γ 
stimulated samples, the FMO controls also do not differ between CB and adult blood. In contrast, there is an induction of pJAK2 in adult, but notCB, CD4+ T cells 
after IFN-γ stimulation. (c) The association between pJAK2+ and STAT1+ CD4+ T cells in relation to age through 14 months. Note that the analysis only included 
infant samples that had sufficient volume to measure both parameters. (D) The associations between pSTAT1+CD4+ T cells and age through 14 months. 
Correlations were determined by Spearman rank test. (e) Representative examples of CB, 6-month-old infant and adult blood samples analyzed by Amnis®-
ImageStreamX for the nuclear localization of STAT1 and pSTAT1 in unstimulated samples (left panels) or after IFN-γ stimulation (right panels). The legend is as 
described in Figure 3.
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and adults (Figure  8). In T(CM) and T(EM/Eff) CD4+ T cells 
of 1-year-old infants, the activation of pSTAT5 remained below 
adult levels after both IL-2 and IL-7 stimulation (Figures 8A,B). 
Consistent with the fact that CD4+ T cell differentiation into 
memory T cells is associated with increased expression of CD25, 
the IL-2Rα, we noted an age-dependent positive correlation 
FigUre 5 | age-dependent changes in JaK/sTaT signaling. (a) The relative increase (Δ) in median pSTAT6 or pSTAT1 activation in infant CD4+ T cells from 
birth to 1 year. (b) A positive correlation (Spearman rank test) between infant age and the pSTAT1:pSTAT6 ratio in infant blood samples that had sufficient blood 
volume to analyze both pSTAT1 and pSTAT6 activation in response to IFN-γ or IL-4 stimulation, respectively. Each symbol represents an individual infant; infants of 
different ages are represented by distinct color symbols as described in Figure 1.
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between IL-2-induced pSTAT5 activation and frequencies 
IL-2Rα+CD4+ T cells (Figure 8C).
DiscUssiOn
To develop novel prevention and intervention strategies aimed 
at reducing neonatal and infant morbidity and mortality, we first 
need to understand how the immune system develops in the 
healthy infant. Toward this goal, the current study defined the 
temporal development of the JAK/STAT signaling function in 
human infant CD4+ T cells from birth to 1 year of age in response 
to specific cytokines. We focused on cytokines important in Th 
cell differentiation, because increased susceptibility to infec-
tious diseases in infants has been associated with Th2-biased 
responses.
Our results suggest that the maturation of the JAK/STAT 
signaling function in infant CD4+ T cells might be regulated 
by common and cytokine-specific factors. Regardless of the 
cytokine tested, the activation of cytokine-specific STAT mol-
ecules was significantly lower in CB CD4+ T cells compared to 
1-year-old infants and to adults. During the first year of life, there 
was a statistically significant age-dependent increase in STAT 
activation, with the most pronounced changes occurring within 
the first 6 months (Table S1 and Figure S2 in Supplementary 
Material). The overall magnitude and the kinetics of changes 
in JAK/STAT signaling function, however, were distinct for 
each cytokine. In addition, the ability to activate the JAK/STAT 
pathway varied dependent on the differentiation status of CD4+ 
T cells.
As different cytokines exert distinct functions, the activation 
of the JAK/STAT signaling pathway will likely be regulated in 
a cytokine-dependent manner, too. Therefore, comparisons in 
the relative activation of the JAK/STAT signaling pathway by 
different cytokines have to consider these factors. Assuming 
that adult CD4+ T cells are fully functional, the activation of 
specific STAT molecules in response to distinct cytokines could 
be considered as 100% response rate. Applying this assumption 
and by expressing the activation of STAT molecules in infant 
CD4+ T cells as a function of STAT activation by the same 
cytokines in adult CD4+ T cells, we can demonstrate cytokine-
dependent differences in JAK/STAT signaling function in infant 
CD4+ T cells (see Figure S4 in Supplementary Material). Among 
the cytokines evaluated, CD4+ T cells at birth showed relatively 
strong activation of the JAK/STAT signaling in response to IL-4 
and also to IL-7, whereas the induction of the JAK/STAT path-
way in response to IL-2, IFN-γ and IL-12 was less developed. The 
obvious question arising is which factors govern these signaling 
differences. We plan to define such factors in future studies; 
their evaluation was outside the scope of the current study as the 
first step was to determine how CD4+ T cell JAK/STAT signaling 
function changes from birth to 1  year in response to distinct 
cytokines.
The differences in the age-dependent increase in STAT acti-
vation by distinct cytokines can be partially explained by the 
preponderance of naïve versus more differentiated CD4+ T cells 
in infants compared to adults. This was most evident in IL-12-
mediated JAK/STAT signaling. Thus, although median frequen-
cies of IL-12-induced pSTAT4+ CD4+ T cells within the naïve 
CD4+ T cell population of CB or blood from 1-year-old infants 
were significantly lower than those in adult CD4+ T cells, median 
frequencies of pSTAT4+CD4+ T(EM/Eff) cells were within 
the range of those induced in adult CD4+ T cells by IL-12 (see 
Figure 6). However, as the majority of CD4+ T cells at 1 year still 
represent naïve CD4+ T cells, this response by memory CD4+ T 
FigUre 6 | il-12-induced psTaT4 activation. (a) The increase in pSTAT4 activation after IL-12 stimulation of CD4+ T cells at birth (n = 18) and 1 year (n = 17); 
adult values (n = 27) are indicated by the gray shaded area with median, 25th, and 75th percentile. (b) Representative composite images of CD4+ T cells from 
6-month-old infants stimulated with media only (top row), or with (bottom row) IL-4, IFN-γ, or IL-12 and analyzed by Amnis®-ImageStreamX for the nuclear 
localization of their relevant transcription factor. Note the distinct nuclear localization of pSTAT6 and pSTAT1 that fills almost the whole nucleus in comparison to only 
partial pSTAT4 nuclear localization. (c) is analogous to (a), but shows the induction of pSTAT4 in T(N), T(CM), and T(EM/Eff) CD4+ T cells. The legend and the 
statistical comparisons are as described in Figures 1 and 2. (D) The relative frequencies of naïve [CD27+, T(N)], central memory [CD27low, T(CM)], and effector 
memory/effector [CD27−, T(EM/Eff)] CD4+ T cell populations of a representative adult and 1-year-old infant and the corresponding histograms of pSTAT4 activation 
after IL-12 stimulation (blue). pSTAT4 frequencies in unstimulated controls are shown by orange histograms.
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FigUre 7 | Differential activation of psTaT5 by il-2 and il-7. (a) Western blot analysis of pJAK3 activation as described in Figure 2c. (b) The age-dependent 
change in pSTAT5+ CD4+T cells from birth to 14 months of age with Spearman rank correlation values. Adult values are shown in comparison and were compared 
to 10- to 14-month-old infants by Mann–Whitney test. (c) Frequencies of pSTAT5+ CD4+T cells in response to in vitro IL-7 stimulation are shown for cord blood 
(n = 11), 4- to 6-month-old (n = 3), and 10- to 14-month-old (n = 7) infants. The gray area indicates median frequencies of adult pSTAT5+ CD4+T (n = 17) with 
borders representing the 25th and 75th percentiles. Each symbol represents an individual subject. Horizontal lines represent median values. Each age group is 
assigned a different symbol as described in Figure 1; Mann–Whitney test was used for between group comparisons. (D,e) Representative composite images of 
CD4+ T cells from 6-month-old infants stimulated with IL-7 (D) or IL-2 (e) and analyzed by Amnis®-ImageStreamX. The response of CD4+ T cells to IL-2 was more 
variable with some cells showing pSTAT5 activation and nuclear localization (left images), whereas other cells remained unresponsive, indicated by lack of nuclear 
staining with pSTAT5 (right images). In contrast, the majority of CD4+ T cells showed pSTAT5 activation and nuclear translocation after IL-7 stimulation.
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cells was masked when only the total CD4+ T cell population was 
analyzed. These results emphasize the importance of comparing 
functional responses in relevant T cell subpopulations.
Naïve and memory CD4+ T cells differ in the expression of 
specific cytokine receptor chains. Yet, the formation of the fully 
assembled cytokine receptor, which consists of multiple distinct 
chains, is required to induce the JAK/STAT signaling pathway. 
Thus, the differences in pSTAT4 activation between naïve and 
memory CD4+ T cells can be explained, at least partially, by 
the lack of the IL-12Rβ2 chain on naive CD4+ T cells (59, 60). 
Similarly, the differential activation of pSTAT5 by IL-2 and 
IL-7 was likely the result of distinct expression levels of the 
IL-2Rα and the IL-7Rα on naïve and memory CD4+ T cells. The 
IL-7Rα is highly expressed on recent thymic emigrants that are 
abundant in the naïve CD4+ T cell population in CB (61). In 
contrast, naïve CD4+ T cells lack the expression of the IL-2Rα 
chain and can therefore only form the intermediate affinity 
IL-2R consisting of the IL-2Rβ and the common γ-chain. As the 
number of activated and differentiated CD4+ T cells increases, 
the high affinity IL-2R complex (IL-2Rαβγ) can be formed and 
pSTAT5 activation will increase concurrently. Indeed, we found 
a significant positive correlation between increasing frequencies 
of IL-2Rα+ and pSTAT5+ CD4+ T cell frequencies from birth to 
1 year of age.
It should be emphasized though that the phenotypic charac-
terization of CD4+ T cells as naïve or memory T cell was not suf-
ficient to explain differences between CD4+ T cells in CB or blood 
samples collected from 1-year-old infants or adults. Again, this 
can be best illustrated when we express the activation of STAT 
molecules in naïve or memory infant CD4+ T cells as percent of 
adult CD4+ T cell responses in the same populations (Figure S5 in 
Supplementary Material). Thus, additional factors likely contrib-
ute to age-dependent changes in JAK/STAT signaling function 
between infant and adult CD4+ T cells.
While the current study examined JAK/STAT signaling in 
response to single cytokines only, in response to an in vivo stimu-
lus, the cytokine milieu will be shaped by the interplay of multiple 
cytokines secreted by diverse cell populations. For example, IFN-
γ, can promote the induction of the IL-12Rβ2 chain on naïve 
CD4+ T cells (59, 60). IL-2-induced pSTAT5 can transcriptionally 
regulate the expression of the IL-12Rβ and IL-4Rα (62, 63), and 
thereby could influence JAK/STAT signaling in response to IL-12 
and IL-4. As our results show that IL-2-induced pSTAT5 activa-
tion, even at 1 year of age, is significantly lower in infant compared 
FigUre 8 | cD4+ T cell differentiation in sTaT5 activation. (a,b) The percentages of T(N), T(CM), and T(EM/Eff) CD4+ T cells that were activated pSTAT5 in 
response to IL-2 (a) or IL-7(b), respectively, in infant blood samples collected at birth and 1 year. Each symbol represents an individual infant; horizontal lines 
represent median values. The gray area indicates median frequencies of adult pSTAT5+ CD4+T cells (n = 17) with borders representing the 25th and 75th 
percentiles. (c) The correlation by Spearman rank test between pSTAT5+CD4+T cells and IL-2Rα+ CD4+ T cells in infant samples of different ages (colored symbols 
as explained in Figure 1). Note that we only included samples that were analyzed for both pSTAT5+ activation and IL-2Rα+ expression.
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to adult CD4+ T cells, it is possible that reduced IL-2 signaling 
impedes the development of optimal Th1 responses in infants 
(Figure S4 in Supplementary Material). One could hypothesize 
that at birth IL-2-induced pSTAT5 would preferentially bind to 
the il4ra promoter because the ifnγ promoter of infant CD4+ T 
cells is hypermethylated (36, 37), but once the methylation status 
changes with age, pSTAT5 could also bind to the ifnγ and/or to 
the il12rβ2 promoters (Figure S4 in Supplementary Material). 
In fact, recent studies have provided evidence of age-dependent 
changes in epigenetic modifications (64, 65).
Some of our results suggest that the JAK/STAT signaling of 
infant CD4+ T cells might contribute to the Th2-biased response 
of infants. We observed relatively strong JAK/STAT signaling 
responses to the Th2 cytokine IL-4 and poorer responses to the 
Th1-driving cytokines IFN-γ and IL-12 in CB, and there was a 
statistically significant increase in the pSTAT1:pSTAT6 ratio from 
birth to 1 year in infant CD4+ T cells. However, to conclusively 
define the role of JAK/STAT signaling in Th cell differentiation, 
future studies should examine signaling events downstream of 
STAT activation, such as the interaction of specific STAT molecules 
with promoter regions of genes important in Th1 cell differentia-
tion (e.g., tbx, il12rβ) and/or changes in epigenetic modification of 
these genes (Figure S4 in Supplementary Material). Furthermore, 
cytokine signals only represent one of the signals driving Th cell 
differentiation. Pathogen type, costimulatory signals by antigen-
presenting cells, antigen concentration, and signals through the 
T cell receptor all influence CD4+ T cell differentiation [e.g., Ref. 
(19, 20, 66–78)].
The fact that the most pronounced changes for all cytokines 
examined occurred within the first 6  months hint at a role of 
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common developmental factors in the regulation and maturation 
of the JAK/STAT signaling function in infant CD4+ T cells. A 
key factor might be the establishment of the infant’s microbiome. 
The importance of the maternal and infant microbiome on infant 
health has become the subject of intense investigation in recent 
years [review examples; Ref. (79–83)]. The infant requires a 
qualitatively distinct response from adults to allow the transition 
from the relatively tolerogenic milieu in the uterus to exposure 
to multiple environmental and pathogenic stimuli after birth. 
Part of this early development is the establishment of the infant’s 
microbiome that may come at the cost of a more suppressive or 
Th2-prone response. In fact, a recent study demonstrated that 
arginase 2-producing CD71 cells suppressed immune activa-
tion in response to host flora in neonates to allow colonization 
with normal flora (84). Similarly, the “layered immune system 
hypothesis” suggests that Tregs, induced to tolerate maternal or 
other antigens transmitted to the fetus in utero, may persist long 
after birth and mediate tolerogenic responses (85, 86).
The above conclusion that major changes in JAK/STAT signal-
ing function occurred within the first 6 months does not rule out, 
however, that changes occurred very early, maybe even within the 
first month of life. Although we were able to obtain a relatively 
large number (n =  169) of healthy infant blood samples, with 
about equal numbers of CB samples (n =  70) and blood from 
1-year-old infants (n  =  64), blood samples from infants age 
0.5 month to 1 year amounted to only about half this number 
(n =  35). Furthermore, <5% of all infant samples represented 
longitudinal samples. The sample size in our study, however, is 
comparable to other studies of immune ontogeny. For example, 
in three different studies examining the ontogeny of Toll-like 
receptor-mediated cytokine responses in human infants was 
defined using longitudinal samples from 35 (87), 30 (88), or 28 
infants (89). Only two of these three studies included samples 
within the first year of life, with one of them sampling at 3-month 
intervals (88), and the other also being able to obtain samples at 2 
and 6 weeks of age (89). The difficulties in obtaining samples from 
healthy infants and blood volume restrictions that limit the analy-
sis scope of such samples constitute a main and common problem 
for investigators and have severely hampered the progress in our 
understanding of immune maturation. Despite our limitations 
in sample size, and by applying conservative non-parametric 
statistical analysis tools, we were able to, nonetheless, demon-
strate broad stages of the temporal development of JAK/STAT 
signaling function in infant CD4+ T cells using. Furthermore, 
trends detected in the analysis of cross-sectional samples were 
consistent with age-dependent changes observed in longitudinal 
sample pairs (Figure S6 in Supplementary Material).
In summary, the current study identified age-related differ-
ences in cytokine signaling and established the time frame during 
which the JAK/STAT signaling function develops in infant CD4+ 
T cells in response to specific cytokines. These data provide the 
foundation for future studies identifying the molecular mecha-
nisms that regulate JAK/STAT signaling in infant CD4+ T cells, 
including, but not limited to, epigenetic regulation (90), the role 
of miRNAs (91, 92), and the regulation of JAK kinases and STAT 
proteins by suppressors of cytokine signaling molecules (93, 94). 
These mechanistic studies were outside the scope of the current 
study. The data highlight how little we still understand about 
the multiple factors that initiate, drive, and regulate CD4+ T cell 
responses in the early postnatal period and the complex interac-
tions between these factors. A deeper insight into postnatal devel-
opment of immune cells and their functions will be instrumental 
for the design of novel therapeutic interventions, will inform the 
timely implementation of novel pediatric vaccines, and thus aid 
in more effectively combating childhood diseases.
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Bank. Direct capillary or venous blood samples (0.5–3.0 mL) from 
infants aged 2 weeks to 14 months were collected by nursing or 
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participants were recruited from the North Carolina population 
that consists of about 46% Caucasians, 46% African-Americans, 
and 8% other groups, and within the ethnic categories, 10% rep-
resent Hispanics. Exclusion criteria included HIV-positive status 
of the mother, known in utero infections, treatment of the mother 
with immunosuppressive drugs, diagnosis of mother or child with 
immunosuppressive disorder, life-threatening malformations of 
the infant or life expectancy <6 months. Infant blood samples were 
also excluded if the infant had a bleeding disorder or had a chronic 
infection. The Virology, Immunology, and Microbiology Core 
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unknown. The study was approved by the UNC-CH Institutional 
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Association’s Declaration of Helsinki.
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FigUre s1 | age-dependent increase in psTaT1 activation. Relative 
frequencies of naïve [CD27+, T(N)], central memory [CD27low, T(CM)], and 
effector memory/effector [CD27−, T(EM/Eff)] CD4+ T cell populations of a 
representative cord blood sample (top row), 1-year-old infant (middle row), and 
an adult (bottom row) and the corresponding histograms of pSTAT1 activation 
after IFN-γ stimulation (blue) are shown. pSTAT1 frequencies in unstimulated 
controls are shown by orange histograms. Note that y-axis scales differ between 
the age groups.
FigUre s2 | correlation between infant age and sTaT activation. From left 
to right, the correlations between infant age (x-axis) and STAT phosphorylation in 
response to IL-4 (pSTAT6), IFN-γ (pSTAT1), and IL-2 (pSTAT5) are graphed, with 
each symbol representing an individual infant and green lines representing 
LOESS curves with a 0.5 smooth factor. These graphs are meant to complement 
Table S1 in Supplementary Material and demonstrate that pSTAT6 and pSTAT1 
activation plateau by about 6 months, whereas there is still a further, although 
slight, increase in pSTAT5 activation from 6 months to 1 year.
FigUre s3 | expression of il-12rb2 on cD4+ T cells. (a) CD3+CD4+ T cells 
of a representative adult donor were stained for CD3+CD4+ T cells expression 
immediately after cell isolation (grey histogram) and after incubation for 48 h with 
a cytokine cocktail consisting of IL-2, IL-12, and IL-15. Note the upregulation of 
the IL-12Rb2 upon cytokine stimulation (blue histogram) compared to CD3+CD4+ 
T cells cultured in media only (orange histogram). (b) To validate the staining, 
CD3-negative cells of the same donor were analyzed for IL-12Rβ2 expression on 
NK cells, defined as CD3-CD14−CD20−CD56+. Note that IL-12Rβ2 expression, in 
contrast to the low expression on CD3+CD4+ T cells, was detectable on the 
majority of NK cells, even immediately after cell isolation. (c) The expression of 
the IL-12Rβ2 on CD3+CD4+ T cells (left histogram) and NK cells (right histogram) 
of a representative cord blood sample. (D) IL-12Rβ2 expression differs among 
NK cell subsets (adult donor example).
FigUre s4 | summary of age-related differences in sTaT signaling and 
conceptual interpretation. Median frequencies of pSTAT positive 
(colored circles) and negative (white) total CD4+ T cells expressed at fraction of 
median frequencies of adult CD4+ T cells, as measured at birth (CB, cord 
blood), 4–6 and 10–14 months. Each square consists of 10 × 10 circles, with 
each circle presenting 1%. The age is listed on the left, the cytokine and the 
cytokine-specific transcription factor are listed on the top of each column. 
IL-4-induced pSTAT6 frequencies are shown in red. The strong Th2 bias at birth 
is represented with the red bar/arrow on the left that is balanced with increasing 
age by an increasing Th1 response (green arrow on right). The most 
pronounced changes in STAT activation occurred in the time from birth to 
6 months; in the subsequent time period from 6 months to 1 year only minor 
changes were noted. This is indicated by the dashed line. We propose that the 
establishment of the microbiome was a key factor driving these changes. In 
addition, other developmentally regulated factors, such as decreasing 
methylation levels on the ifnγ promoter region, likely contributed to an increase 
in STAT signaling. Increasing exposure to danger signals (pathogens, 
environmental stimuli, pediatric vaccines, etc.) drive the activation of CD4+ T 
cells and results in a changing ratio of naïve and memory CD4+ T cells. 
Activated and more differentiated CD4+ T cells express higher levels of certain 
cytokine receptors (e.g., IL-2Rα, IL-12Rβ) allowing for more effective pSTAT5 
activation and signaling. We propose that at birth pSTAT5 may predominantly 
activate the il4 and il4ra genes, while with increasing age pSTAT5 will be able to 
activate to also activate ifnγ and il12rβ genes and thereby, promote Th1 
responses. This figure is meant to summarize our data and present some 
factors that may have contributed to the observed age-related changes in JAK/
STAT signaling function and present a potential role of IL-2 in driving Th1 
development in infants. Other factors are likely important in postnatal 
development of JAK/STAT signaling; this figure is by no means exhaustive. The 
complex interplay between these factors and other immune cells was outside 
the scope of the current study.
FigUre s5 | changes in sTaT activation in infant cD4+ T cell 
subpopulation from birth to 1 year. Analogous to Figure S4 in Supplementary 
Material, median frequencies of pSTAT positive (colored circles) and negative 
(white) naïve [T(N)], central memory [T(CM)], and effector memory/ effector [T(EM/
Eff)] CD4+ T cells are expressed at fraction of median frequencies of adult CD4+ T 
cell subpopulations at birth (CB, cord blood) and 1 year of age (10–14 months). 
Each square consists of 10 × 10 circles, with each circle presenting 1%. The 
CD4+ T cell subpopulations are listed on the column top and the cytokine with its 
relevant transcription factor are listed on the left. The color coding is as 
described in Figure S4 in Supplementary Material.
FigUre s6 | age-dependent changes in sTaT activation in longitudinal 
infant blood samples. (a) The frequencies of pSTAT6, pSTAT1, and pSTAT5+ 
CD4+ T cells after stimulation of longitudinal samples from the same infant with 
IL-4, IFN-γ, or IL-2, respectively. Samples from the same infant are represented 
by the same symbol and longitudinal data points are connected by a black line. 
(b) Representative histograms of samples shown in panel (A) are depicted.
18
dela Peña-Ponce et al. Infant CD4+ T Cell Cytokine Signaling
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 15
12. Zaghouani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers 
and the shortcomings of dendritic cells. Trends Immunol (2009) 30:585–91. 
doi:10.1016/j.it.2009.09.002 
13. Adkins B. Heterogeneity in the CD4 T cell compartment and the variability 
of neonatal immune responsiveness. Curr Immunol Rev (2007) 3:151–9. 
doi:10.2174/157339507781483496 
14. Marchant A, Goldman M. T cell-mediated immune responses in 
human newborns: ready to learn? Clin Exp Immunol (2005) 141:10–8. 
doi:10.1111/j.1365-2249.2005.02799.x 
15. Lewis DB, Yu CC, Meyer J, English BK, Kahn SJ, Wilson CB. Cellular and 
molecular mechanisms for reduced interleukin 4 and interferon-gamma 
production by neonatal T cells. J Clin Invest (1991) 87:194–202. doi:10.1172/
JCI114970 
16. Lederer JA, Perez VL, DesRoches L, Kim SM, Abbas AK, Lichtman AH. 
Cytokine transcriptional events during helper T cell subset differentiation. 
J Exp Med (1996) 184:397–406. doi:10.1084/jem.184.2.397 
17. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell (1994) 
76:241–51. doi:10.1016/0092-8674(94)90332-8 
18. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood (2008) 
112:1557–69. doi:10.1182/blood-2008-05-078154 
19. Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks 
of cytokines and transcription factors. Immunol Rev (2010) 238:247–62. 
doi:10.1111/j.1600-065X.2010.00951.x 
20. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell 
populations (*). Annu Rev Immunol (2010) 28:445–89. doi:10.1146/
annurev-immunol-030409-101212 
21. Agnello D, Lankford CS, Bream J, Morinobu A, Gadina M, O’Shea JJ, et al. 
Cytokines and transcription factors that regulate T helper cell differentiation: 
new players and new insights. J Clin Immunol (2003) 23:147–61. doi:10.102
3/A:1023381027062 
22. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ 
T cells to enhance priming for interferon gamma production and diminishes 
interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A (1993) 
90:10188–92. doi:10.1073/pnas.90.21.10188 
23. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. 
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-
induced macrophages. Science (1993) 260:547–9. doi:10.1126/science.8097338 
24. Sornasse T, Larenas PV, Davis KA, de Vries JE, Yssel H. Differentiation 
and stability of T helper 1 and 2 cells derived from naive human neonatal 
CD4+ T cells, analyzed at the single-cell level. J Exp Med (1996) 184:473–83. 
doi:10.1084/jem.184.2.473 
25. Lee HH, Hoeman CM, Hardaway JC, Guloglu FB, Ellis JS, Jain R, et al. Delayed 
maturation of an IL-12-producing dendritic cell subset explains the early 
Th2 bias in neonatal immunity. J Exp Med (2008) 205:2269–80. doi:10.1084/
jem.20071371 
26. Marodi L. Innate cellular immune responses in newborns. Clin Immunol 
(2006) 118:137–44. doi:10.1016/j.clim.2005.10.012 
27. Petty RE, Hunt DW. Neonatal dendritic cells. Vaccine (1998) 16:1378–82. 
doi:10.1016/S0264-410X(98)00095-4 
28. Upham JW, Lee PT, Holt BJ, Heaton T, Prescott SL, Sharp MJ, et al. Development 
of interleukin-12-producing capacity throughout childhood. Infect Immun 
(2002) 70:6583–8. doi:10.1128/IAI.70.12.6583-6588.2002 
29. Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third 
signal for clonal expansion of naive CD8 T cells. J Immunol (2002) 169:6842–9. 
doi:10.4049/jimmunol.169.12.6842 
30. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin 
(IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 
cells. J Exp Med (1997) 185:817–24. doi:10.1084/jem.185.5.817 
31. Murphy KM, Murphy TL, Szabo SJ, Jacobson NG, Guler ML, Gorham JD, 
et  al. Regulation of IL-12 receptor expression in early T-helper responses 
implies two phases of Th1 differentiation: capacitance and development. Chem 
Immunol (1997) 68:54–69. doi:10.1159/000058694 
32. Berrington JE, Barge D, Fenton AC, Cant AJ, Spickett GP. Lymphocyte subsets 
in term and significantly preterm UK infants in the first year of life analysed 
by single platform flow cytometry. Clin Exp Immunol (2005) 140:289–92. 
doi:10.1111/j.1365-2249.2005.02767.x 
33. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm 
ER, et al. Lymphocyte subsets in healthy children from birth through 18 years 
of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin 
Immunol (2003) 112:973–80. doi:10.1016/j.jaci.2003.07.003 
34. Goriely S, Van Lint C, Dadkhah R, Libin M, De Wit D, Demonte D, et al. A defect 
in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal 
dendritic cells. J Exp Med (2004) 199:1011–6. doi:10.1084/jem.20031272 
35. Goriely S, Vincart B, Stordeur P, Vekemans J, Willems F, Goldman M, et al. 
Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal 
monocytes. J Immunol (2001) 166:2141–6. doi:10.4049/jimmunol.166.3.2141 
36. White GP, Hollams EM, Yerkovich ST, Bosco A, Holt BJ, Bassami MR, et al. CpG 
methylation patterns in the IFNgamma promoter in naive T cells: variations 
during Th1 and Th2 differentiation and between atopics and non-atopics. Pediatr 
Allergy Immunol (2006) 17:557–64. doi:10.1111/j.1399-3038.2006.00465.x 
37. White GP, Watt PM, Holt BJ, Holt PG. Differential patterns of methylation of 
the IFN-gamma promoter at CpG and non-CpG sites underlie differences in 
IFN-gamma gene expression between human neonatal and adult CD45RO- T 
cells. J Immunol (2002) 168:2820–7. doi:10.4049/jimmunol.168.6.2820 
38. Webster RB, Rodriguez Y, Klimecki WT, Vercelli D. The human IL-13 locus in 
neonatal CD4+ T cells is refractory to the acquisition of a repressive chroma-
tin architecture. J Biol Chem (2007) 282:700–9. doi:10.1074/jbc.M609501200 
39. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine 
signaling and myeloproliferative disorders: approaches for targeted therapies. 
Genes Cancer (2010) 1:979–93. doi:10.1177/1947601910397187 
40. Duncan SA, Zhong Z, Wen Z, Darnell JE Jr. STAT signaling is active during 
early mammalian development. Dev Dyn (1997) 208:190–8. doi:10.1002/
(SICI)1097-0177(199702)208:2<190::AID-AJA6>3.0.CO;2-D 
41. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat 
Rev Immunol (2003) 3:900–11. doi:10.1038/nri1226 
42. Stow JL, Murray RZ. Intracellular trafficking and secretion of inflammatory 
cytokines. Cytokine Growth Factor Rev (2013) 24:227–39. doi:10.1016/j.
cytogfr.2013.04.001 
43. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev 
Cancer (2004) 4:11–22. doi:10.1038/nrc1252 
44. Murray PJ. The JAK-STAT signaling pathway: input and output integration. 
J Immunol (2007) 178:2623–9. doi:10.4049/jimmunol.178.5.2623 
45. Boulay JL, O’Shea JJ, Paul WE. Molecular phylogeny within type I cytokines 
and their cognate receptors. Immunity (2003) 19:159–63. doi:10.1016/
S1074-7613(03)00211-5 
46. Mullings RE, Wilson SJ, Puddicombe SM, Lordan JL, Bucchieri F, Djukanovic 
R, et al. Signal transducer and activator of transcription 6 (STAT-6) expression 
and function in asthmatic bronchial epithelium. J Allergy Clin Immunol (2001) 
108:832–8. doi:10.1067/mai.2001.119554 
47. Notarangelo LD, Mella P, Jones A, de Saint Basile G, Savoldi G, Cranston T, 
et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 
deficiency. Hum Mutat (2001) 18:255–63. doi:10.1002/humu.1188 
48. Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, et al. STAT3 deletion 
during hematopoiesis causes Crohn’s disease-like pathogenesis and lethality: 
a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A (2003) 
100:1879–84. doi:10.1073/pnas.0237137100 
49. Malek TR, Porter BO, He YW. Multiple gamma c-dependent cytokines 
regulate T-cell development. Immunol Today (1999) 20:71–6. doi:10.1016/
S0167-5699(98)01391-7 
50. Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, 
et al. Impaired response to interferon-alpha/beta and lethal viral disease in 
human STAT1 deficiency. Nat Genet (2003) 33:388–91. doi:10.1038/ng1097 
51. Miller DM, Rahill BM, Boss JM, Lairmore MD, Durbin JE, Waldman JW, 
et  al. Human cytomegalovirus inhibits major histocompatibility complex 
class II expression by disruption of the Jak/Stat pathway. J Exp Med (1998) 
187:675–83. doi:10.1084/jem.187.5.675 
52. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. 
Oncogene (2007) 26:6724–37. doi:10.1038/sj.onc.1210757 
53. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional acti-
vation in response to IFNs and other extracellular signaling proteins. Science 
(1994) 264:1415–21. doi:10.1126/science.8197455 
54. Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F, Rahim F. STATs: an old 
story, yet mesmerizing. Cell J (2015) 17:395–411. 
55. Jensen K, Pena MG, Wilson RL, Ranganathan UD, Jacobs WR Jr, Fennelly G, 
et al. A neonatal oral Mycobacterium tuberculosis-SIV prime / intramuscular 
MVA-SIV boost combination vaccine induces both SIV and Mtb-specific 
19
dela Peña-Ponce et al. Infant CD4+ T Cell Cytokine Signaling
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 15
immune responses in infant macaques. Trials Vaccinol (2013) 2:53–63. 
doi:10.1016/j.trivac.2013.09.005 
56. Marthas ML, Van Rompay KK, Abbott Z, Earl P, Buonocore-Buzzelli L, Moss 
B, et al. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral 
SIV challenge in infant macaques. Vaccine (2011) 29:3124–37. doi:10.1016/j.
vaccine.2011.02.051 
57. Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, Lipsky PE. Stepwise 
differentiation of CD4 memory T cells defined by expression of CCR7 and 
CD27. J Immunol (2005) 175:6489–97. doi:10.4049/jimmunol.175.10.6489 
58. Zola H, Fusco M, Weedon H, Macardle PJ, Ridings J, Roberton DM. Reduced 
expression of the interleukin-2-receptor gamma chain on cord blood lympho-
cytes: relationship to functional immaturity of the neonatal immune response. 
Immunology (1996) 87:86–91. 
59. Wu CY, Gadina M, Wang K, O’Shea J, Seder RA. Cytokine regulation 
of IL-12 receptor beta2 expression: differential effects on human 
T and NK cells. Eur J Immunol (2000) 30:1364–74. doi:10.1002/
(SICI)1521-4141(200005)30:5<1364::AID-IMMU1364>3.0.CO;2-U 
60. Yamane H, Igarashi O, Kato T, Nariuchi H. Positive and negative 
regulation of IL-12 receptor expression of naive CD4(+) T cells by 
CD28/CD152 co-stimulation. Eur J Immunol (2000) 30:3171–80. 
doi:10.1002/1521-4141(200011)30:11<3171::AID-IMMU3171>3.0.CO;2-C 
61. Opiela SJ, Koru-Sengul T, Adkins B. Murine neonatal recent thymic emigrants 
are phenotypically and functionally distinct from adult recent thymic emi-
grants. Blood (2009) 113:5635–43. doi:10.1182/blood-2008-08-173658 
62. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the 
complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr 
Opin Immunol (2011) 23:598–604. doi:10.1016/j.coi.2011.08.003 
63. Liao W, Lin JX, Wang L, Li P, Leonard WJ. Modulation of cytokine receptors by 
IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 
(2011) 12:551–9. doi:10.1038/ni.2030 
64. Martino DJ, Tulic MK, Gordon L, Hodder M, Richman TR, Metcalfe J, et al. 
Evidence for age-related and individual-specific changes in DNA methylation 
profile of mononuclear cells during early immune development in humans. 
Epigenetics (2011) 6:1085–94. doi:10.4161/epi.6.9.16401 
65. Lissner MM, Thomas BJ, Wee K, Tong AJ, Kollmann TR, Smale ST. Age-
related gene expression differences in monocytes from human neonates, 
young adults, and older adults. PLoS One (2015) 10:e0132061. doi:10.1371/
journal.pone.0132061 
66. Gajewski TF, Schell SR, Nau G, Fitch FW. Regulation of T-cell activation: 
differences among T-cell subsets. Immunol Rev (1989) 111:79–110. 
doi:10.1111/j.1600-065X.1989.tb00543.x 
67. Gajewski TF, Joyce J, Fitch FW. Antiproliferative effect of IFN-gamma in 
immune regulation. III. Differential selection of TH1 and TH2 murine helper 
T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. 
J Immunol (1989) 143:15–22. 
68. Murray JS, Madri J, Tite J, Carding SR, Bottomly K. MHC control of CD4+ 
T cell subset activation. J Exp Med (1989) 170:2135–40. doi:10.1084/
jem.170.6.2135 
69. Kelly CD, Russo CM, Rubin BY, Murray HW. Antigen-stimulated human 
interferon-gamma generation: role of accessory cells and their expressed or 
secreted products. Clin Exp Immunol (1989) 77:397–402. 
70. Farrar JD, Ranganath SH, Murphy KM. Molecular mechanisms in T helper 
phenotype development. Springer Semin Immunopathol (1999) 21:211–30. 
doi:10.1007/BF00812254 
71. Grakoui A, Donermeyer DL, Kanagawa O, Murphy KM, Allen PM. TCR-
independent pathways mediate the effects of antigen dose and altered peptide 
ligands on Th cell polarization. J Immunol (1999) 162:1923–30. 
72. Guler ML, Gorham JD, Dietrich WF, Steen RG, Parvin C, Fenoglio D, et al. 
Loci influencing development of Th responses. Identification from in  vitro 
analysis. Microbes Infect (1999) 1:79–88. doi:10.1016/S1286-4579(99)80018-5 
73. Murphy KM, Ouyang W, Szabo SJ, Jacobson NG, Guler ML, Gorham JD, et al. 
T helper differentiation proceeds through Stat1-dependent, Stat4-dependent 
and Stat4-independent phases. Curr Top Microbiol Immunol (1999) 238:13–26. 
74. Corthay A. A three-cell model for activation of naive T helper cells. Scand 
J Immunol (2006) 64:93–6. doi:10.1111/j.1365-3083.2006.01782.x 
75. Nakayama T, Yamashita M. The TCR-mediated signaling pathways that 
control the direction of helper T cell differentiation. Semin Immunol (2010) 
22:303–9. doi:10.1016/j.smim.2010.04.010 
76. O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and 
plasticity of helper CD4+ T cells. Science (2010) 327:1098–102. doi:10.1126/
science.1178334 
77. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and ampli-
fied? Nat Rev Immunol (2010) 10:225–35. doi:10.1038/nri2735 
78. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res (2010) 
20:4–12. doi:10.1038/cr.2009.138 
79. Bergstrom A, Skov TH, Bahl MI, Roager HM, Christensen LB, Ejlerskov KT, 
et al. Establishment of intestinal microbiota during early life: a longitudinal, 
explorative study of a large cohort of Danish infants. Appl Environ Microbiol 
(2014) 80:2889–900. doi:10.1128/AEM.00342-14 
80. Lim ES, Zhou Y, Zhao G, Bauer IK, Droit L, Ndao IM, et al. Early life dynamics 
of the human gut virome and bacterial microbiome in infants. Nat Med (2015) 
21:1228–34. doi:10.1038/nm.3950 
81. Neu J. The microbiome during pregnancy and early postnatal life. Semin Fetal 
Neonatal Med (2016) 21(6):373–9. doi:10.1016/j.siny.2016.05.001 
82. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by micro-
biota in early life shapes the immune system. Science (2016) 352:539–44. 
doi:10.1126/science.aad9378 
83. Yang I, Corwin EJ, Brennan PA, Jordan S, Murphy JR, Dunlop A. The infant 
microbiome: implications for infant health and neurocognitive development. 
Nurs Res (2016) 65:76–88. doi:10.1097/NNR.0000000000000133 
84. Elahi S, Ertelt JM, Kinder JM, Jiang TT, Zhang X, Xin L, et al. Immunosuppressive 
CD71+ erythroid cells compromise neonatal host defence against infection. 
Nature (2013) 504:158–62. doi:10.1038/nature12675 
85. Mold JE, McCune JM. At the crossroads between tolerance and aggression: 
revisiting the “layered immune system” hypothesis. Chimerism (2011) 
2:35–41. doi:10.4161/chim.2.2.16329 
86. Mold JE, Michaelsson J, Burt TD, Muench MO, Beckerman KP, Busch 
MP, et  al. Maternal alloantigens promote the development of tolerogenic 
fetal regulatory T cells in  utero. Science (2008) 322:1562–5. doi:10.1126/
science.1164511 
87. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, Kallos A, et al. Ontogeny 
of toll-like receptor mediated cytokine responses of human blood mononu-
clear cells. PLoS One (2010) 5:e15041. doi:10.1371/journal.pone.0015041 
88. Nguyen M, Leuridan E, Zhang T, De Wit D, Willems F, Van Damme P, et al. 
Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. 
PLoS One (2010) 5:e10407. doi:10.1371/journal.pone.0010407 
89. Reikie BA, Adams RC, Ruck CE, Ho K, Leligdowicz A, Pillay S, et al. Ontogeny 
of toll-like receptor mediated cytokine responses of South African infants 
throughout the first year of life. PLoS One (2012) 7:e44763. doi:10.1371/
journal.pone.0044763 
90. Tuomela S, Lahesmaa R. Early T helper cell programming of gene expression 
in human. Semin Immunol (2013) 25:282–90. doi:10.1016/j.smim.2013.10.013 
91. Baumjohann D, Ansel KM. microRNA-mediated regulation of T helper cell 
differentiation and plasticity. Nat Rev Immunol (2013) 13:666–78. doi:10.1038/
nri3494 
92. Pagani M, Rossetti G, Panzeri I, de Candia P, Bonnal RJ, Rossi RL, et al. Role 
of microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation. 
Immunol Rev (2013) 253:82–96. doi:10.1111/imr.12055 
93. Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular 
regulation of Janus kinase (JAK) activation. Biochem J (2014) 462:1–13. 
doi:10.1042/BJ20140712 
94. Starr R, Hilton DJ. SOCS: suppressors of cytokine signalling. Int J Biochem Cell 
Biol (1998) 30:1081–5. doi:10.1016/S1357-2725(98)00067-3 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 dela Peña-Ponce, Rodriguez-Nieves, Bernhardt, Tuck, Choudhary, 
Mengual, Mollan, Hudgens, Peter-Wohl and De Paris. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
